Aakash Desai Announces Launch of DISCERN Trial in Lung Cancer at UAB O’Neal Comprehensive Cancer Center
Aakash Desai, Associate Director at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn about a recent paper published on ScienceDirect:
“Thrilled to announce my investigator-initiated clinical trial in lung cancer ‘DISCERN’ is now active UAB O’Neal Comprehensive Cancer Center!
We’re exploring new ground in treating PD-L1 negative advanced non-small cell lung cancer. This trial, DISCERN, focuses on early ctDNA response to compare dual vs. single immunotherapy plus chemotherapy. Excited to see how this research can improve patient outcomes!”
Title: DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non–Small Cell Lung Cancer
Authors: Aakash Desai, Ellen McNeeley, Sanad Alhushki, Mia Haught, Xavier Masojan Juncos, Dhartiben Patel, Jeffery Brand, Leigh McManus, Sejong Bae, Maya Khalil, Yanis Boumber.
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023